One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
Table 2
Visual outcomes, CRT, and number of injections at month 3 and month 12.
PRN group
LD group
P value
Month 3
Change of BCVA (mean ± SD)
8.4 ± 11.9
11.9 ± 11.8
0.157
CRT (μm, mean ± SD)
327.2 ± 155.0
283.4 ± 127.2
0.139
Change in CRT from baseline
−140.8 ± 192.3
−144.7 ± 109.5
0.903
Increase of ≥15 letters (%)
31.1%
38.8%
0.605
Decrease of ≥15 letters (%)
2.2%
0
0.479
Mean no. of injections
2.4
3.0
<0.01
Month 12
Change of BCVA (mean ± SD)
7.8 ± 16.0
10.9 ± 15.8
0.344
CRT (μm, mean ± SD)
308.7 ± 122.3
308.6 ± 138.6
0.999
Change in CRT from baseline
−159.3 ± 204.2
−120.5 ± 127.1
0.257
Increase of ≥15 letters (%)
28.9%
44.9%
0.066
Decrease of ≥15 letters (%)
6.7%
6.1%
1.000
Mean no. of injections
6.0
6.8
0.275
BCVA, best-corrected visual acuity; CRT, central retinal thickness; LD, loading doses; PRN, pro re nata; SD, standard deviation.
